Biocon has informed that it enclosed the press release dated on October 04, 2021 titled ‘Biocon expands its Generic Formulations portfolio with the launch of Everolimus tablets in the US’. The above information will also be available on the website of the Company at www.biocon.com.
The above information is a part of company’s filings submitted to BSE.